A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833

Inclusion Criteria

Biopsy proven advanced cancer, for whom no better therapy exists.

Enrollment of patients with breast cancer, lymphoma, renal cell cancer or ovarian cancer
are encouraged.

Patients with a life expectancy of at least 16 weeks, and a performance status (Karnofsky
Scale) of 70% or greater. No rapidly growing disease.

Patients with prior therapy.

WBC greater than 3,000/mm(3) and AGC greater than 1000/mm(3); platelets greater than
100,000/mm(3).

Creatinine clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than
90 u/L; SGPT less than 100 u/L.

Patients must sign an informed consent and have geographic accessibility to return for
follow up and treatment.

No history of brain metastases.

No patients currently receiving treatment with the following agents or any other agent
known to significantly interact with cyclosporine, and the treatment cannot be
discontinued , or changed to another therapeutically equivalent allowable drug:
acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole,
ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides,
trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.

No patients with a history of coronary artery disease with angina pectoris or history of
congestive heart failure.

No patients with a history of cardiac disease, other than angina pectoris or congestive
heart failure, including patients with arrhythmias or conduction system abnormalities will
be considered on an individual basis.

No patients with symptomatic peripheral neuropathy (grade 2 or greater).

No patients with a positive serology for HIV.

No patients who are pregnant or unwilling to practice adequate contraception.

No patients with prior bone marrow transplantation or extensive irradiation resulting in
compromised bone marrow reserve.